TY - JOUR
T1 - Clinical trial end points in malignant glioma
T2 - Need for effective trial design strategy
AU - Brada, M.
AU - Yung, W. K.A.
N1 - Copyright:
Copyright 2007 Elsevier B.V., All rights reserved.
PY - 2000
Y1 - 2000
N2 - Although oncologists have devised a number of measures of therapeutic efficacy, the design and evaluation of clinical trials of therapy for malignant gliomas present special difficulties. These include comparability of study design, patient stratification, classification of tumor type, and outcome response measures. In addition, these tumors and their treatment have profound effects on patients' quality of life. Consequently, considerations of quality of life are an important factor in study design. These issues are addressed to facilitate the interpretation of current and future studies of emerging treatment options in patients with malignant gliomas. Copyright (C) 2000 by W.B. Saunders Company.
AB - Although oncologists have devised a number of measures of therapeutic efficacy, the design and evaluation of clinical trials of therapy for malignant gliomas present special difficulties. These include comparability of study design, patient stratification, classification of tumor type, and outcome response measures. In addition, these tumors and their treatment have profound effects on patients' quality of life. Consequently, considerations of quality of life are an important factor in study design. These issues are addressed to facilitate the interpretation of current and future studies of emerging treatment options in patients with malignant gliomas. Copyright (C) 2000 by W.B. Saunders Company.
UR - http://www.scopus.com/inward/record.url?scp=0034080126&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034080126&partnerID=8YFLogxK
M3 - Article
C2 - 10866345
AN - SCOPUS:0034080126
SN - 0093-7754
VL - 27
SP - 11
EP - 19
JO - Seminars in oncology
JF - Seminars in oncology
IS - 3 SUPPL. 6
ER -